BR9812609A - Nucleotide sequence, polypeptide, use of a polypeptide, processes of preparation of a polypeptide and of evidence or isolation of compounds capable of modulating or inhibiting the interaction between presenilins and polypeptides, host cell for the production of polypeptide, anti- oligonucleotide sense, nucleotide probe, antibody or antibody fragment, ligand of a polypeptide, use of a ligand, defective recombinant virus, vector, and pharmaceutical composition - Google Patents

Nucleotide sequence, polypeptide, use of a polypeptide, processes of preparation of a polypeptide and of evidence or isolation of compounds capable of modulating or inhibiting the interaction between presenilins and polypeptides, host cell for the production of polypeptide, anti- oligonucleotide sense, nucleotide probe, antibody or antibody fragment, ligand of a polypeptide, use of a ligand, defective recombinant virus, vector, and pharmaceutical composition

Info

Publication number
BR9812609A
BR9812609A BR9812609-1A BR9812609A BR9812609A BR 9812609 A BR9812609 A BR 9812609A BR 9812609 A BR9812609 A BR 9812609A BR 9812609 A BR9812609 A BR 9812609A
Authority
BR
Brazil
Prior art keywords
polypeptide
ligand
antibody
presenilins
evidence
Prior art date
Application number
BR9812609-1A
Other languages
Portuguese (pt)
Inventor
Luc Mercken
Laurent Pradier
Alain Fournier
Marie-Francoise Paul
Original Assignee
Aventis Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Sa filed Critical Aventis Pharma Sa
Priority claimed from PCT/FR1998/002093 external-priority patent/WO1999016874A1/en
Publication of BR9812609A publication Critical patent/BR9812609A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein

Abstract

"SEQUêNCIA NUCLEOTìDICA, POLIPEPTìDEO, UTILIZAçãO DE UM POLIPEPTìDEO, PROCESSOS DE PREPARAçãO DE UM POLIPEPTìDEO E DE EVIDENCIAMENTO OU DE ISOLAMENTO DE COMPOSTOS CAPAZES DE MODULAR OU DE INIBIR A INTERAçãO ENTRE AS PRESENILINAS E OS POLIPEPTìDEOS, CéLULA HOSPEDEIRA PARA A PRODUçãO DE POLIPEPTìDEO, OLIGONUCLEOTìDEO ANTI-SENTIDO, SONDA NUCLEOTìDICA, ANTICORPO OU FRAGMENTO DE ANTICORPO, LIGANTE DE UM POLIPEPTìDEO, UTILIZAçãO DE UM LIGANTE, VìRUS RECOMBINANTE DEFECTIVO, VETOR, E, COMPOSIçãO FARMACêUTICA". A presente invenção refere-se a novas sequências nucleotídicas e peptídicas, e sua utilização farmacêutica. Mais particularmente, a presente invenção refere-se a ácidos nucleicos que codificam para proteínas capazes de interagir com as presenilinas."NUCLEOTHYDICAL SEQUENCE, POLYPEPTIDE, USE OF A POLYPEPTIDE, PROCEDURES FOR PREPARING A POLYPEPTIDE AND FOR THE EVIDENCE OR ISOLATION OF COMPOUNDS ABLE TO MODULAR OR INHIBIT THE INTERACTION BETWEEN THE PREVENTION AND THE POLYPOTHYLES - DIRECTION, NUCLEOTHYDIC PROBE, ANTIBODY OR ANTIBODY FRAGMENT, BINDER OF A POLYPEPTIDE, USE OF A BINDER, DEFECTIVE RECOMBINANT VIRUS, AND PHARMACEUTICAL COMPOSITION ". The present invention relates to new nucleotide and peptide sequences, and their pharmaceutical use. More particularly, the present invention relates to nucleic acids that encode proteins capable of interacting with presenilins.

BR9812609-1A 1997-10-01 1998-09-30 Nucleotide sequence, polypeptide, use of a polypeptide, processes of preparation of a polypeptide and of evidence or isolation of compounds capable of modulating or inhibiting the interaction between presenilins and polypeptides, host cell for the production of polypeptide, anti- oligonucleotide sense, nucleotide probe, antibody or antibody fragment, ligand of a polypeptide, use of a ligand, defective recombinant virus, vector, and pharmaceutical composition BR9812609A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9712221A FR2769021B1 (en) 1997-10-01 1997-10-01 NUCLEIC ACIDS ENCODING PROTEINS CAPABLE OF INTERACTING WITH PRESENILINS
PCT/FR1998/002093 WO1999016874A1 (en) 1997-10-01 1998-09-30 Nucleic acids coding for proteins capable of interacting with presenilins

Publications (1)

Publication Number Publication Date
BR9812609A true BR9812609A (en) 2000-08-01

Family

ID=9511686

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9812609-1A BR9812609A (en) 1997-10-01 1998-09-30 Nucleotide sequence, polypeptide, use of a polypeptide, processes of preparation of a polypeptide and of evidence or isolation of compounds capable of modulating or inhibiting the interaction between presenilins and polypeptides, host cell for the production of polypeptide, anti- oligonucleotide sense, nucleotide probe, antibody or antibody fragment, ligand of a polypeptide, use of a ligand, defective recombinant virus, vector, and pharmaceutical composition

Country Status (4)

Country Link
BR (1) BR9812609A (en)
FR (1) FR2769021B1 (en)
PL (1) PL339645A1 (en)
ZA (1) ZA988974B (en)

Also Published As

Publication number Publication date
FR2769021B1 (en) 2000-12-15
ZA988974B (en) 1999-04-07
PL339645A1 (en) 2001-01-02
FR2769021A1 (en) 1999-04-02

Similar Documents

Publication Publication Date Title
Shaulian et al. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation.
Rothhut Participation of annexins in protein phosphorylation
NO864369D0 (en) POLYPEPTIDES COMPLEMENTARY TO PEPTIDES OR PROTEINS WHICH HAVE AN AMINO ACID SEQUENCE OR A NUCLEOTIDE CODING SEQUENCE THAT IS AT LEAST PARTLY KNOWN.
DK0758383T3 (en) Soluble polypeptide fractions of the LAG-3 protein; method of manufacture; therapeutic composition; anti-idiotypic antibody
HUP9801122A2 (en) Osteoprotegerin
DE69326064D1 (en) Human protein P53 peptides for use in human cytotoxic T cell response inducing compositions and human P53 protein specific T lymphocytes
WO1997024436A3 (en) Ligand polypeptides for the g-protein-coupled receptor protein, their production and use
Jörnvall et al. The adenovirus hexon protein. The primary structure of the polypeptide and its correlation with the hexon gene.
BR9508714A (en) Compound process for preparing streptograms by muta-synthesis nucleotide sequence recombinant DNA vector use of a mutant strain sequence and / or polypeptide vector and pharmaceutical composition
BR9810917A (en) Isolated polypeptide, fusion protein, expression vector, cultured cell, process to produce a polypeptide, pharmaceutical composition, antibody, binding protein, isolated polynucleotide, and oligonucleotide probe or primer
PT1079849E (en) USE OF HMG PROTEINS FOR THE PREPARATION OF MEDICINES WITH CYTOTOXIC ACTIVITY
Fukai et al. Rat plasma fibronectin contains two distinct chemotactic domains for fibroblastic cells
Mackey et al. Studies on the mechanism of DNA linking by Epstein-Barr virus nuclear antigen 1
BR9510067A (en) Peptide capable of interacting with the sh3 domain of the antibody gap protein or antibody fragment directed against a polypeptide nucleotide sequence encoding an antisense nucleic acid polypeptide capable of at least partially inhibiting the production of polypeptides its use pharmaceutical composition and use of an antibody or antibody fragment
Sekimizu et al. Difference in phosphorylation of two factors stimulating RNA polymerase II of Ehrlich ascites tumor cells
AU7017494A (en) Purified mammalian flt3 ligands and agonists and antagonists thereof
BR9812609A (en) Nucleotide sequence, polypeptide, use of a polypeptide, processes of preparation of a polypeptide and of evidence or isolation of compounds capable of modulating or inhibiting the interaction between presenilins and polypeptides, host cell for the production of polypeptide, anti- oligonucleotide sense, nucleotide probe, antibody or antibody fragment, ligand of a polypeptide, use of a ligand, defective recombinant virus, vector, and pharmaceutical composition
AU5623801A (en) 3d structure of polypeptides containing a tpr-structure motif with chaperone-binding function, crystals thereof and compounds for inhibition of said peptides
ZA943920B (en) Pharmaceutical compositions
Ichimura et al. Isolation and some properties of a 34‐kDa‐membrane protein that may be responsible for ribosome binding in rat liver rough microsomes
DE69925116D1 (en) NEW, PHYSIOLOGICAL ACTIVE PEPTIDES AND THEIR USE.
WO1998054302A3 (en) Human lysophosphatidic acid acyltransferase
WO2002055669A3 (en) Regulation of target protein activity through modified proteins
Freire et al. Phosphorylation of prothymosin α. An approach to its biological significance
Allewell High resolution studies of E. coli aspartate transcarbamoylase come of age

Legal Events

Date Code Title Description
B08F Application fees: dismissal - article 86 of industrial property law

Free format text: REFERENTE A 6O,7O,8O E 9O ANUIDADES

B08K Lapse as no evidence of payment of the annual fee has been furnished to inpi (acc. art. 87)

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1909 DE 07/08/2007.